| Place of Origin: | China |
|---|---|
| Brand Name: | Senwayer Brand |
| Certification: | ISO, 9001, USP |
| Model Number: | 89778-27-8 |
| Minimum Order Quantity: | 10grams |
| Price: | Discount is possible if your order is big enough |
| Packaging Details: | 10g, 20g, 50g , 100g, 500g. 1kg, 10kg |
| Delivery Time: | within 2 working days |
| Payment Terms: | T/T in advance, Money Gram, Western Union, Bank Transfer. |
| Supply Ability: | 1000kg/month |
| CAS: | 89778-27-8 | Alias: | Fareston , Toremifene Citrate |
|---|---|---|---|
| Apparence: | Almost White Crystalline Powder | Purity: | 99% |
| High Light: | antineoplastic drugs,breast cancer drugs |
||
Toremifene Citrate Breast Cancer Cure and Protection Fareston 89778-27-8 SERM
Quick detail
Product name Toremifene Citrate
Other name FC 1157a; Fareston; NK 622; NSC 613680
CAS register number 89778-27-8
Molecular formula C26H28ClNO.C6H8O7
Molecular weight 598.09
Assay 99%
Appearance White or almost white powder
Package 1kg/aluminium foil bag or as required
Usage Can be used as pharmaceutical material
Minimum order quantity 10g
Shipping By express courier
Shipping leading time Within 24 hours after receiving the payment
Payment options Western Union , MoneyGram , T/T , Bitcoin
Price Negotiated
Fareston—A Once-Daily Tablet Taken by Mouth
Toremifene Citrate Description:
Toremifene Citrate is a Selective Estrogen Receptor Modulator (SERM) best known by the popular trade name given to it by GTx Inc. Fareston. Very similar to Nolvadex (Tamoxifen Citrate) and Clomid (Clomiphene Citrate), Fareston is medically used to treat breast cancer in post-menopausal women. Toremifene Citrate is also used in many performance enhancing circles for side effect protection and post cycle therapy plans. This does not make Fareston an anabolic steroid; however, it is commonly used by steroid users in order to enhance the safety and efficiency of their steroid use.
Anabolic steroid users often use Fareston in order to prevent estrogenic related side effects that may be caused by the use of aromatizing steroids. Many steroids, particularly testosterone and testosterone based have the ability to aromatize. Aromatization refers to the conversion of testosterone to estrogen, and as estrogen levels rise this can lead to complications. The most common estrogenic issues include gynecomastia and water retention. High blood pressure can also occur when water retention gets out of hand, but Toremifene Citrate can help with all of these things.
Fareston Application
| 1 | Toremifene is used in postmenopausal women to treat breast cancer that has spread to other parts of the body (metastatic breast cancer). |
| 2 | It is usually used to treat cancerthat needs estrogen, a female hormone, in order to grow (estrogen-receptor positive). |
| 3 |
How to use toremifene?
Related ANTI-ESTROGEN product:
| Tamoxifen Citrate (Nolvadex) | CAS:54965-24-1 |
| Clomiphene citrate | CAS:50-41-9 |
| Toremifene citrate | CAS:50-41-9 |
| Exemestane(Aromasin) | CAS:107868-30-4 |
| Anastrozole (Arimidex) | CAS:120511-73-1 |
| Letrazole(Femara) | CAS:120511-73-1 |
| Methoxydienone | CAS:2322-77-2 |
| Estradiol | CAS:50-28-2 |
| Norgestrel | CAS:6533-00-2 |
Fareston is contraindicated in patients with known hypersensitivity to the drug, and in patients with congenital/acquired QT prolongation (long QT syndrome), uncorrected hypokalemia, or uncorrected hypomagnesemia.
Warnings and Precautions
Fareston has been shown to prolong the QT interval. Caution should be exercised in patients with congestive heart failure, hepatic impairment and electrolyte abnormalities. In patients at increased risk, ECGs should be obtained at baseline and as clinically indicated.
Hypercalcemia and tumor flare have been reported during the first weeks of treatment with Fareston in some breast cancer patients with bone metastases. If hypercalcemia is severe, Fareston treatment should be discontinued.
Patients with preexisting endometrial hyperplasia should not be given long-term Fareston treatment, and patients at high risk for endometrial cancer should be closely monitored.
Patients with a history of thromboembolic diseases should not be treated with Fareston.
Leukocyte and platelet counts should be monitored when using Fareston in patients with leukopenia and thrombocytopenia.
Fareston can cause fetal harm when administered to a pregnant woman.
Fareston is only indicated for postmenopausal women. However, premenopausal women prescribed Fareston should use effective nonhormonal contraception and should be apprised of the potential hazard to the fetus should pregnancy occur.
